Autori: Grubinger T
| Naslov | Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phase III "ISTAHIT" trial (Meeting Abstract) |
| Autori | Petzer Andreas L Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D  Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Grubinger T Kwakkelstein Marthin Rancati Francesca Gastl Guenther A Wolf Dominik
|
| Info | ONKOLOGIE, (2011), vol. 34 br. , Suppl. 6, str. 264-264 |
| Ispravka | Web of Science Elečas Rang časopisa Citati: Web of Science |
     |
